Ascentage Pharma Group International

AAPG · HONG

$15.44+$0.52 (+3.49%)TodayMarket closed · Oct 23, 7:30 PM ET

Prev close $14.92

About AAPG

Ascentage Pharma Group International Co., Ltd. is a clinical-stage biotechnology company. The company is headquartered in Suzhou, Jiangsu and currently employs 767 full-time employees. The company went IPO on 2019-10-28. The firm's main products include Olverembatinib (HQP1351), Lisaftoclax (APG-2575), Alrizomadlin (APG-115), Pelcitoclax (APG-1252), APG-5918, and APG-2449. The firm's products are primarily used to treat chronic myeloid leukemia (CML), acute myeloid leukemia (AML), chronic lymphocytic leukemia (CLL), acute lymphoblastic leukemia (ALL), myelodysplastic syndrome (MDS) and multiple myeloma (MM). The firm primarily conducts its businesses in domestic market.

Employees: 767
Headquarters: Suzhou, Jiangsu
Listed: Oct 28, 2019
Sector: Health Care
Industry: Biotechnology
Website: ascentage.cn

Leadership

Ascentage Pharma Group International executives
Name	Title	Since	Age
Dajun Yang	—	2017	62
Thomas Knapp	—	—	72
Jin Cao	—	—	39
Raymond Kmetz	—	—	67
Yifan Zhai	—	—	62
Charmayne Chan	—	—	—
Shaomeng Wang	—	—	61
Marina Bozilenko	—	—	60
Marc Lippman	—	—	80
Dazhong Lu	—	—	56
Wei Ren	—	—	44
David Sidransky	—	—	64
Changqing Ye	—	—	54
Debra Yu	—	—	60

Information on this page is provided for informational purposes only and is not a recommendation to buy, sell or hold any security. Investing involves risk, including possible loss of principal. Market data is delayed at least 15 minutes and is provided without warranty. Analyst ratings, price targets and company data come from third-party sources. Past performance does not guarantee future results.